新型冠状病毒感染后肺纤维化的发病机制及相关治疗  

Pathogenesis and related treatment of pulmonary fibrosis after novel coronavirus infection

作　　者：虎梅 王艳[1] 张建银[1] 杨静[1] 耑冰[1] HU Mei;WANG Yan;ZHANG Jianyin;YANG Jing;ZHUAN Bing(Department of Respiratory Medicine,Ningxia Hui Autonomous Region People's Hospital,Yinchuan Ningxia 750001,China)

机构地区：[1]宁夏回族自治区人民医院呼吸内科,宁夏银川750001

出　　处：《实用心电学杂志》2023年第4期283-288,共6页Journal of Practical Electrocardiology

摘　　要：新型冠状病毒感染是一种具有高度传染性的呼吸道疾病,主要累及肺部。该疾病进展可能与促炎介质(如细胞因子)的过度释放有关,进而造成肺部损伤,导致急性呼吸窘迫综合征和呼吸衰竭,严重威胁患者的生命健康。肺纤维化是新型冠状病毒感染幸存者长期面临的肺部后遗症,也是导致新型冠状病毒肺炎加重的重要危险因素之一。本文对新型冠状病毒感染后肺纤维化的发病机制及相关治疗的研究进展进行综述。Novel coronavirus infection is a highly infectious respiratory disease,which mainly affects the lungs.The progression of this disease is probably related to the excessive release of inflammatory mediators(such as cytokines),which further causes lung deterioration resulting in acute respiratory distress syndrome and respiratory failure,seriously threatening patients'lives.Pulmonary fibrosis is a long-term pulmonary sequela faced by the survivors of critical illness from novel coronavirus infection.It is also one of important risk factors leading to the aggravation of corona virus disease 2019.This article summarizes the research advances in the pathogenesis and treatment of pulmonary fibrosis after novel coronavirus infection.

关 键 词：新型冠状病毒感染 肺纤维化 发病机制 抗纤维化治疗 

分 类 号：R511[医药卫生—内科学] R563.9[医药卫生—临床医学]